Regeneron Pharmaceuticals Files 8-K on Financials

Ticker: REGN · Form: 8-K · Filed: 2025-10-06T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations

Related Tickers: REGN

TL;DR

REGN filed an 8-K on Oct 6, 2025, for financial and operational updates.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, to report on its results of operations and financial condition. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these updates.

Why It Matters

This filing indicates that Regeneron is providing an update on its financial performance and operational status to the SEC and the public.

Risk Assessment

Risk Level: low — The filing is a standard procedural document and does not disclose any new material risks or adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Regeneron Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report on Regeneron Pharmaceuticals, Inc.'s results of operations and financial condition.

On what date was this 8-K report filed?

This 8-K report was filed on October 6, 2025.

What is the principal executive office address for Regeneron Pharmaceuticals, Inc.?

The principal executive office address for Regeneron Pharmaceuticals, Inc. is 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.

In which state was Regeneron Pharmaceuticals, Inc. incorporated?

Regeneron Pharmaceuticals, Inc. was incorporated in New York.

What is the telephone number listed for Regeneron Pharmaceuticals, Inc.?

The telephone number listed for Regeneron Pharmaceuticals, Inc. is (914) 847-7000.

From the Filing

0001104659-25-096921.txt : 20251006 0001104659-25-096921.hdr.sgml : 20251006 20251006070049 ACCESSION NUMBER: 0001104659-25-096921 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251006 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20251006 DATE AS OF CHANGE: 20251006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 251375580 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 tm2528010d1_8k.htm FORM 8-K false 0000872589 0000872589 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 6, 2025 ( October 6, 2025 )   REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)   New York (State or other jurisdiction of incorporation)   000-19034   13-3444607 (Commission File Number)   (I.R.S. Employer Identification No.)     777 Old Saw Mill River Road , Tarrytown , New York   10591-6707 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 914 ) 847-7000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 2.02.   Results of Operations and Financial Condition.   Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2025 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $83 million on a pre-tax basis. This charge primarily relates to the previously disclosed $80 million

View on Read The Filing